LATEST NEWS
February 19, 2025: ‘Radiance rolls into ROR1 race, paying $15M for ADC rival to Merck’s frontrunner‘ – Fierce Biotech
More……
February 19, 2025: ‘Radiance Biopharma Enters Exclusive License For ROR-1 Targeted Antibody Drug Conjugate‘ – GlobalNewswire
More……
January 8, 2024: ‘Biocytogen enters into Bispecific Antibody Drug Conjugate Agreement with Radiance Biopharma‘ – Businesswire
More……
Radiance Biopharma’s mission is to develop a pipeline of next generation Antibody Drug Conjugates (ADCs) for the treatment of cancer and other high unmet medical needs.
Radiance’s Board of Directors, Management and Advisors are industry veterans with experience in both large pharma and biotechnology startups and are committed to transforming the lives of patients with cancer.
RB-164™ is a ‘First-in-class’ ADC targeting ROR-1 which uses proprietary conjugation/linker technologies and the monomethyl auristatin E payload. Learn more
RB-201™ is a ‘First-in-class’ fully human Bispecific ADC targeting both HER2 and TROP-2 conjugated to the monomethyl auristatin E payload. Learn more
RB-203™ is a proprietary monoclonal antibody recognizing membrane Hsp70 which is expressed on the majority of tumors, but not normal cells. Learn more